Precision Healthcare at Your Fingertips
We understand that healthcare costs can be a significant barrier to getting the right treatment. That’s why we work directly with pharmaceutical companies and healthcare providers to offer affordable treatment options. By leveraging AI and data analytics, we make life-saving treatments more accessible, ensuring that everyone has the opportunity to get the care they need.
This leads to dosage issues such as increased costs and higher mortality rates.
- Side effects of drugs
- Causing an increase of 15% more use of hospital beds
- Costing $30 billion extra in the USA, and £3Billion in the UK
- 5% of additional hospital visits in the USA, UK and EU
- Resulting in more non-responsive patients, with delayed treatments, and deaths.
- Creating more discomfort for patients.
Disease progression depends on individual factors including genetic,
genomic, proteomic, and environmental factors. These need different
dosages and different therapeutics during their progression.
Precision medicine‘s first step is toward making personalised medicine dosages relevant to the specific patient by implementing large data setanalysis.
Personalised medicine aims at using the genetic profile of the
individual patient to better treat the disease.
The Problem is that the current drug arsenal utilise approximately (~8,000 to 20,000 APIs) is not sufficient to treat any disease (~35,000), nor to include diseases’ progress levels which would require at least (~100,000).
Consequently, the promise of personalised treatments require a huge expansion of the repository drug arsenal.
CureLogic AI is an integrated Platform as a Service (PaaS) that combines all our services, effectively creating a one-stop solution for personalized medicine. The PaaS consists of our proprietary technology coupled with a CRISPR platform running on a supercomputer which validates the proposed microRNA Signature drug treatment plan on the patient’s own (diseased) cells; thus achieving a Rapid turnover capable of performing the tasks within 2-3 weeks.
CureLogic AI – PaaS is addressed to:
Each Hospital treat in general yearly:
- 3,450 Cancer patients
- 857 Heart disease patients
- 3,600 Genetic diseases
Current treatments pricing:
- €196,000 – €446,000 / patient
Our drug treatment pricing:
- €18,000/IM Injection
We intend to set our pricing near the following price points and offer our treatments also to the less fortunate in our society at €18,000.
Let’s assume that we only get 1% of their patients to sign the waiver for experimental drug treatment to participate in our clinicaltrial in Asia, Africa, and South America.
CureLogic AI – PaaS
- €5,000 monthly
While completing our clinical trials in the Netherlands and the UK, in the first year of commercialisation, and identifying a major pharmaceutical partner to handle regulators worldwide for us, CureLogic intends to gain traction with 10 Hospitals/Clinics/Home Care Facilities in Asia, Africa, and South America via our marketing partners on these territories.
10 hospitals/clinics will generate €43.2M / year
having their dying patients sign a waiver, recognising the experimental drug treatment as a last resource for survival, we will gain more cases to be added to our clinical trials to increase our cohorts to successful completion rapidly.
10 hospitals x €5,000/month + (€18,000/vaccine x 3 treatments vaccines)= ARR =€600,000/year + €43.2M/year (at 1% of the potential clientele= 80patients)
= €43.2 Million a year
Freemium & 6 Months PaaS Licensing
- Revenue : 1.375M
- Market : 50 Hospitals Clinics Universities
Treatment Plans
- Revenue : 0M
- Market : 0 Hospitals Clinics Home Care
CURE Advanced Payments Treatment Plans
- Revenue : 1.08M
- Market : 60 Insurance/Individuals /Hospitals
According to industrial reports, the precision medicine market was valued at: €78.85 in 2021 and increasing to €278 billion in 2028 with a steady rate of annual growth of 12.5% from 2024 onward
- TAM = €120 Billion
- SAM = €40 Billion
- SOM = €10 Billion
- UK = €0.8 Billion
- EU = €5.0 Billion
- USA= €4.2 Billion
| Summary - Basic | |||
|---|---|---|---|
| Year 1 | Year 2 | Year 3 | |
| Total Income | €2,455,000 | €94,870,500 | €105,182,550 |
| Total Outgoings | €2,656,830 | €6,001,404 | €5,868,726 |
| Net Profit/Loss (pre TAX and Dividends) | -€201,830 | €88,869,096 | €99,313,824 |